Revenio Group Oyj - Annual Financial Report

Revenio Group Corporation: Annual report 2016 has been published

Revenio Group Corporation, Annual Financial Report, March 1, 2017 at 11:00

Revenio Group Corporation's Annual report 2016 has been published

Revenio Group Corporation's Annual report 2016 has been published. The report,
available in Finnish and English in PDF format on the corporations' website at
www.revenio.fi and as an attachment to this stock exchange release, contains
financial statements for the corporation and parent company, the report of the
Board of Directors, auditors report and a report on corporate governance.

The AR will be published in print in week 12. To order a copy, place an order
with Revenio Group Corporation, Äyritie 22, FI-01510 Vantaa or by e-mail
elina.kari@revenio.fi.

Revenio Group Corporation
Timo Hildén
President and CEO

For further information, please contact:
President & CEO Timo Hildén
tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on intraocular pressure measurement technology that
has a strong patent. Revenio Group consists of, in addition to the parent
company, Icare Finland Oy which focuses on intraocular pressure measurement
technology and its fully owned subsidiary Icare USA Inc., research and
development company Revenio Research Oy and Oscare Medical Oy, in which Revenio
holds a 53.5% interest. The common denominators of Revenio's business operations
include screening, follow-up, and the global need to make cost savings through
preventive health care. Revenio seeks vigorous growth in health technology.
Revenio aims to develop even more efficient and easily adopted methods for the
early-stage detection of diseases with significance for public health. The focus
of Revenio's screening technology is on the early detection of glaucoma,
osteoporosis, skin cancer, and asthma, and the monitoring of these during the
treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating margin
for continuing operations standing at 30.1% from continuous operations. Revenio
Group Corporation is listed on Nasdaq Helsinki.


[]

Attachments:

Revenio Group Corporation Annual report 2016.pdf